Oncology Brothers: Practice-Changing Cancer Discussions

FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.Key topics included:• The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3.• Study design and findings from the EPCOR FL1 trial.• Step-up dosing schedule and its implications for patient management.• Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).• The role of minimal residual disease (MRD) and ctDNA in treatment decisions.Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

Challenging Cases in Second Line & Beyond Renal Cell Carcinoma (RCC) - Dr. David Braun

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases.
We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines.
Key topics included:• The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment• The impact of disease progression on treatment decisions• Side effect management and the importance of palliative care• The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios
Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology. 
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers!
#RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology

FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.
Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including:• The significance of the study in the context of recent FDA approvals and treatment advancements.• Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab.• The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes.• Management of side effects and clinical pearls for practitioners.
We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions.
Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to like, share, and subscribe for more practice-changing updates in oncology!
#MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology

Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky

In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings.
Key topics included:• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting.
Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and send us your challenging cases for future discussions!
#CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive

Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer.
Key topics included:
The definition and characteristics of high-risk non-muscle invasive bladder cancer.
Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment.
The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach.
Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy.
Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes.
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!
#NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer

FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML). 
We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML.
Key topics covered in this episode included:
The mechanism of action of Ziftomenib as a menin inhibitor
Study findings from KOMET-001 and patient response rates
Management of side effects, including differentiation syndrome and QTc prolongation
Comparison with other menin inhibitors like Revumenib
Future directions for combination therapies and sequencing of treatments
Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information. 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights.
#Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers

Managing Toxicities of ROS1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) – Dr. Estela Rodriguez

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients.
Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:• The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC.• A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib.• Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity.• Clinical pearls for managing adverse events and optimizing patient care.• The significance of patient education and regular follow-ups in ensuring treatment adherence and safety.Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC.
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice!
#ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer

Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML).
Join us as we delve into:• An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.• Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias.• Unique side effects associated with each TKI and strategies for dose optimization.• The importance of patient education and monitoring to ensure effective management of side effects.
Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more!
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care!
#CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine

Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer.
Episode Highlights:
MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach.
FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with chemotherapy for EGFR-positive NSCLC.
SOHO-01 & Beamion LUNG-1: emerging HER2-positive NSCLC treatments, Zongertinib and Sevabertinib.
Discussion on the significance of NGS testing in identifying mutations and tailoring treatment options for patients.
Join us as we explore these important studies and their implications for improving patient outcomes in lung cancer care. 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to subscribe for more updates on practice-changing research and major conference highlights!
#ESMO2025 #LungCancer #NSCLC #MDT #Zongertinib #Sevabertinib #Osimertinib #OncologyBrothers

GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice.
Episode Highlighted:•⁠  ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer.•⁠  ⁠STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities.•⁠  ⁠MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies.•⁠  ⁠FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma.
Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care. 
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms.
#ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine